Abstract:Introduction: Children with H3K27-altered diffuse midline gliomas (DMG-H3K27a), have a 5-year survival rate of only 2% following diagnosis. While in-depth genomic characterization has been performed in DMG-H3K27a, very few druggable targets have been identified. A common feature of DMG-H3K27a is infiltration of microglia, macrophages, other myeloid cells, collectively referred to as GAMs. Cellular crosstalk between non-tumor and tumor cells in the tumor microenvironment (TME) can both promote and or inhibit tumor growth, thus representing an opportunity in the pursuit of novel therapeutics. We have recently determined that DMG-H3K27a tumor cells stimulate microglial secretion of pro-tumor growth factors. Hypothesis: Microglial-derived growth factors activate receptor tyrosine kinases (RTKs) via paracrine signaling in DMG-H3K27a. Methods: We used scRNA-seq and RNA-seq datasets and, in parallel, in vitro studies, such as co-culture studies, ELISA assays, western blotting, and growth assays to test our hypothesis. In addition, we are developing a mouse-human chimeric neutralizing antibodies of our top targets for in vivo studies. Preliminary Results: Microglial cells secrete growth factors into the TME, which promotes DMG-H3K27a cell proliferation and growth. Targeting growth factors with neutralizing antibodies attenuates glioma cell proliferation in co-culture studies. Conclusion: This research uncovers an important signaling network between GAMs and DMG-H3K27a that can be therapeutically targeted. Citation Format: Andrea Cruz, Brenden Johnson, Taylor Gatesman, Mathew Halbert, Suchet Taori, Baoli Hu, Gary Kohanbash, Ian F. Pollack, Sameer Agnihotri. The role of tumor microenvironment derived growth factors in pediatric brain tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB307.

Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma

Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas

From protein-protein interactions to immune modulation: Therapeutic prospects of targeting Neuropilin-1 in high-grade glioma

Cnsc-43. Neurotransmitter Dependency Underlies Tumor Growth In Humanized Pediatric Low-Grade Glioma Models

Neuroligin 3 Regulates Dendritic Outgrowth by Modulating Akt/mTOR Signaling.

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant

Abstract LB307: The role of tumor microenvironment derived growth factors in pediatric brain tumors

Neuronal-driven glioma growth requires Gαi1 and Gαi3

The neurobiology of gliomas: from cell biology to the development of therapeutic approaches

Electrical and synaptic integration of glioma into neural circuits

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas

A High Notch Pathway Activation Predicts Response to γ Secretase Inhibitors in Proneural Subtype of Glioma Tumor‐Initiating Cells

Glutamatergic synaptic input to glioma cells drives brain tumour progression

Non-coding RNAs as Key Regulators of the Notch Signaling Pathway in Glioblastoma: Diagnostic, Prognostic, and Therapeutic Targets

Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme

The multifaceted therapeutical role of low‐density lipoprotein receptor family in high‐grade glioma

Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas

A prognostic neural epigenetic signature in high-grade glioma

Glioma synapses recruit mechanisms of adaptive plasticity

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma

Integrating Machine Learning and Mendelian Randomization Determined a Functional Neurotrophin-Related Gene Signature in Patients with Lower-Grade Glioma